Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.
Lonza said it has extended a contract to produce monoclonal antibodies for an unnamed “major pharmaceutical partner.” If the asset is approved for commercialization, the CDMO will use its new facility in Visp, Switzerland, which is expected to finish construction this year, according to a Tuesday release. The partners’ original deal was signed in 2021.
Lonza also said that its capsules and health ingredients division is not performing as well because of customers de-stocking hard capsule manufacturing. Nonetheless, the company said during its earnings call Thursday that it expects a “high level” number of contracts overall for 2024.
Rentschler Biopharma announced on Thursday it is building a new 34,000 square meter facility at its headquarters in Laupheim, Germany. The factory’s construction will start in spring 2025 and will be fully operational by 2028. It will be used for manufacturing buffer solutions and other media.
Siegfried’s new CEO Marcel Imwinkelried, who joined on Sept. 1, outlined his vision for the company on Thursday. It plans on focusing on commercial manufacturing as well as broadening its technology offerings for drug substance production, Imwinkelried said.
Grifols has secured a new partnership with the Biomedical Advanced Research and Development Authority to test eye drops for mustard gas exposure, according to a Tuesday announcement.
Radioisotope producer Actineer has manufactured the radioisotope actinium-225 for the first time, the company said Friday. Ac-225 will be available to customers by the middle of next year. Actineer is a joint venture between radiopharma company ITM and nuclear tech company Canadian Nuclear Laboratories.
Sartorius reported a 2% decline in sales to $2.47 billion for its third quarter revenue last Thursday. This is compared to the $2.54 billion it reported in the same period last year. The drop is mainly attributed to its lab products and services division because of weak markets, especially in China.